Synergistic inhibitory effect of Icariside II with Icaritin from Herba Epimedii on pre-osteoclastic RAW264.7 cell growth |
| |
| Institution: | 1. College (Institue) of Integrative Medicine, Dalian Medical University, Dalian 116044, China;2. Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China;3. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China;1. Department of Integrative Medicine, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China;2. Edward Ford Building A27, Sydney Medical School, The University of Sydney, New South Wales 2006, Australia;3. Shanghai Geriatrics Institute, Huadong Hospital, Fudan University, 221 West Yanan Road, Shanghai 200040, China;4. Department of Dermatology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China;1. Department of Integrative Medicine, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China;2. Shanghai Institute of Geriatrics Medicine, Huadong Hospital, Fudan University, 221 South Yanan Road, Shanghai 200400, China;1. Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders and State Key Disciplines, Medical College of Qingdao University, Qingdao 266071, People’s Republic of China;2. Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, People’s Republic of China;3. Department of Special Medicine, Medical College of Qingdao University, Qingdao, People’s Republic of China;4. Department of Physiology, Medical College of Taishan, Taian, People’s Republic of China;1. Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, Hubei Province 430072, PR China;2. Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei Province 430056, PR China;3. College of Bioengineering, Wuhan Polytechnic, Wuhan, Hubei Province 430074, PR China |
| |
| Abstract: | Increasing evidence shows the therapeutic superiority of herbal extracts in comparison to isolated single constituents. One of the reasons may be attributed to the synergy effect of compound combinations. Flavonoids from Herba Epimedii have been shown to have therapeutic effect against bone loss. Our previous study showed that Icariside II inhibited pre-osteoclast RAW264.7 growth. The aim of this study was to investigate whether the activity of Icariside II is synergized by other components of Herba Epimedii. The inhibitory activity of Icariside II was significantly enhanced in the presence of the extract of Herba Epimedii (EHE) at the ratio of 1:1, 1:5 and 1:10. Icaritin, another flavonoid constituent, was shown here to inhibit RAW264.7 growth in a dose-dependent manner. Further, we found that Icariside II, together with Icaritin, synergistically inhibited RAW264.7 growth. The synergistic effect is significant when the ratio of Icariside II and Icaritin was 10:1, 5:1, 1:1, 1:2, and 1:5, respectively. In conclusion, Icaritin were an active component. The inhibitory activity of Icariside II on pre-osteoclast RAW264.7 growth was synergized by Icaritin, which maybe contribute to the efficiency of Herba Epimedii extract on curing bone-related diseases, such as osteoporosis |
| |
| Keywords: | Herba Epimedii Icaritin Icariside II RAW264 7 Synergy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
